Related references
Note: Only part of the references are listed.Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
Maintaining Safety with SARS-CoV-2 Vaccines
Mariana C. Castells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Covid-19: AstraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine Agency
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL (2021)
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
Victoria Furer et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials
Jin Kyun Park et al.
CLINICAL RHEUMATOLOGY (2020)
Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment
Sanket Shah et al.
RHEUMATOLOGY INTERNATIONAL (2020)
Evaluation of SARS-CoV-2 serology assays reveals a range of test performance
Jeffrey D. Whitman et al.
NATURE BIOTECHNOLOGY (2020)
Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations
Christien Rondaan et al.
RMD OPEN (2019)
Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial
Jin Kyun Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
mRNA vaccines - a new era in vaccinology
Norbert Pardi et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial
Jin Kyun Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses
H. C. Rumke et al.
VACCINE (2011)
T cell responses are better correlates of vaccine protection in the elderly
JE McElhaney et al.
JOURNAL OF IMMUNOLOGY (2006)
Share Paper
